When Will Retatrutide Be Available?
Short answer: Retatrutide is not FDA-approved and has no confirmed availability date. TRIUMPH-1 Phase 3 topline results were announced May 21, 2026. Eli Lilly announced plans for a Q1 2027 regulatory submission to the FDA. Approval and commercial availability are not guaranteed and depend on the full regulatory review process. The only legal way to access retatrutide today is through an authorized clinical trial.
Quick Answers
Where can you get retatrutide?
As of September 2026, the only legal source of retatrutide in the United States is an authorized clinical trial registered on ClinicalTrials.gov. No pharmacy, telehealth provider, or online vendor can legally supply retatrutide. Participants in authorized trials receive pharmaceutical-grade retatrutide at no cost under medical supervision.
Retatrutide is an investigational drug — it has not received FDA approval and is not commercially available. Eli Lilly plans to submit a regulatory application in Q1 2027. Until approval, the only pathway is a registered trial. See our step-by-step guide: How to Find a Legitimate Retatrutide Clinical Trial.
Can you buy retatrutide online?
No. Websites offering retatrutide for sale are selling unapproved, unverified substances. The FDA has issued warning letters to vendors of unapproved GLP-1 compounds. Products sold online as retatrutide cannot be verified for identity, potency, sterility, or safety. Purchasing from these sources carries serious legal and health risks.
Independent testing has found products sold as retatrutide that contained no retatrutide at all — in one documented case, a product contained semaglutide at approximately eight times the normal dose. See: Online Retatrutide and Peptide Sellers and Fake and Illicit Retatrutide.
How much will retatrutide cost in the United States?
No commercial price has been announced. Based on comparable approved GLP-1/GIP drugs (semaglutide at $900–$1,000/month, tirzepatide at $1,000–$1,400/month), analysts project a list price of $800–$1,500 per month. Actual out-of-pocket cost will depend on insurance coverage, formulary placement, and any manufacturer savings programs Eli Lilly introduces after approval.
For a detailed breakdown of cost projections, insurance landscape, and access pathways, see Retatrutide Cost and Insurance.
Where to get retatrutide for free right now
Authorized clinical trials provide pharmaceutical-grade retatrutide at no cost to enrolled participants. Study-related visits, labs, and procedures are typically covered by the trial sponsor. You should never pay to participate in a legitimate clinical trial. Search ClinicalTrials.gov for NCT05929066 (TRIUMPH-1), NCT05929079 (TRIUMPH-2), or NCT05882045 (TRIUMPH-3) to check enrollment status.
Step-by-step enrollment guidance: How to Find a Legitimate Retatrutide Clinical Trial. For eligibility criteria and trial status: TRIUMPH Phase 3 Clinical Trials Center.
Key Facts
The FDA Approval Pathway
Before retatrutide can be prescribed or sold in the United States, Eli Lilly must complete Phase 3 clinical trials, compile the results into a regulatory application, submit it to the FDA, and receive approval.
TRIUMPH-1 (obesity) reported topline results May 21, 2026: 28.3% mean weight loss at 80 weeks. TRIUMPH-2 (T2D + obesity) and TRIUMPH-3 (severe obesity + cardiovascular disease) reported topline results July 23, 2026. Eli Lilly reports five positive Phase 3 studies. Peer-reviewed publications pending.
Eli Lilly plans to submit a regulatory application to the FDA in Q1 2027. Lilly states it has the clinical data package needed to support global submissions for obesity, knee osteoarthritis pain, and obstructive sleep apnea. This is a company-announced plan, not an FDA commitment.
Standard FDA review takes approximately 10–12 months from application acceptance. Priority Review (if granted) takes approximately 6 months.
If approved, Eli Lilly can begin commercial manufacturing and distribution. Approval is not guaranteed.
Typically follows approval by weeks to months, depending on manufacturing scale-up and distribution logistics.
How to Access Retatrutide Today
The only legal way to receive retatrutide in the United States is to enroll in an authorized clinical trial. Trials are conducted at approved research sites, supervised by licensed investigators, and monitored by the FDA. Participants receive the drug at no cost and contribute to the evidence base that will determine whether retatrutide is approved.
To find currently enrolling trials, see our guide: How to Find a Legitimate Retatrutide Clinical Trial.
Warning: Vendors Claiming to Sell Retatrutide
Any vendor claiming to sell, compound, or supply retatrutide outside of a clinical trial is operating illegally under federal law.
- Compounding pharmacies (503A or 503B) — retatrutide has no approved NDA and cannot be legally compounded
- Telehealth companies offering retatrutide prescriptions
- Online peptide vendors selling research-grade retatrutide
- International pharmacies or gray-market suppliers
For more on the legal and safety risks, see Online Retatrutide and Peptide Sellers and Can Retatrutide Be Compounded?
What About Cost and Insurance?
No pricing has been announced for retatrutide. For context, comparable approved drugs have US list prices of $900–$1,400/month before insurance. Insurance coverage for obesity drugs varies widely. For a detailed breakdown, see Retatrutide Cost and Insurance.
Frequently Asked Questions
When will retatrutide be available?
Retatrutide is not FDA-approved and is not commercially available. TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 have reported positive topline Phase 3 results. Eli Lilly plans to submit a regulatory application to the FDA in Q1 2027. If the application is accepted and approved under standard review (10–12 months), commercial availability could follow in 2028. This is speculative — approval is not guaranteed.
Can I get retatrutide now?
Retatrutide is only available to participants enrolled in authorized clinical trials. It cannot be prescribed, dispensed, or purchased outside of a trial. Any vendor claiming to sell retatrutide is selling an unapproved, unverified substance.
Where can I get retatrutide legally?
The only legal source of retatrutide in the United States is an authorized clinical trial registered on ClinicalTrials.gov. Participants receive pharmaceutical-grade retatrutide at no cost under medical supervision. No pharmacy, telehealth provider, or online vendor can legally supply retatrutide as of September 2026.
How much will retatrutide cost?
No pricing has been announced. Comparable approved drugs (semaglutide, tirzepatide) have list prices of $900–$1,400/month in the US before insurance. Retatrutide pricing will depend on FDA approval, Eli Lilly's commercial strategy, and payer negotiations.
Can you buy retatrutide online?
No legitimate source sells retatrutide online. Websites offering retatrutide for sale are selling unapproved, unverified substances. The FDA has issued warning letters to vendors of unapproved GLP-1 compounds. Purchasing from these sources carries serious legal and health risks.
Will insurance cover retatrutide?
Unknown. Coverage for obesity drugs varies widely by insurer and plan. Whether retatrutide will be covered — and at what tier — will depend on its approved indications and payer negotiations at the time of launch.
What is the TRIUMPH Phase 3 program?
TRIUMPH is Eli Lilly's Phase 3 clinical trial program for retatrutide. TRIUMPH-1 (obesity) reported topline results May 21, 2026. TRIUMPH-2 (T2D + obesity) and TRIUMPH-3 (severe obesity + cardiovascular disease) reported topline results July 23, 2026. Eli Lilly reports five positive Phase 3 studies and states it has the clinical data package needed to support global submissions for obesity, knee osteoarthritis pain, and obstructive sleep apnea.
How do I find a retatrutide clinical trial?
Search ClinicalTrials.gov for "retatrutide" or "LY3437943" to find currently enrolling trials. See our guide on how to find a legitimate retatrutide clinical trial for step-by-step instructions.